These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 28597399)

  • 41. Effect of levosimendan on survival and adverse events after cardiac surgery: a meta-analysis.
    Harrison RW; Hasselblad V; Mehta RH; Levin R; Harrington RA; Alexander JH
    J Cardiothorac Vasc Anesth; 2013 Dec; 27(6):1224-32. PubMed ID: 24050857
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Preoperative levosimendan in heart failure patients undergoing noncardiac surgery.
    Katsaragakis S; Kapralou A; Markogiannakis H; Kofinas G; Theodoraki EM; Larentzakis A; Menenakos E; Theodorou D
    Neth J Med; 2008 Apr; 66(4):154-9. PubMed ID: 18424862
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Levosimendan versus dobutamine in heart failure patients treated chronically with carvedilol.
    Duygu H; Turk U; Ozdogan O; Akyuz S; Kirilmaz B; Alioglu E; Gunduz R; Bozkaya YT; Turkoglu C; Payzin S
    Cardiovasc Ther; 2008; 26(3):182-8. PubMed ID: 18786088
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty.
    Samimi-Fard S; García-González MJ; Domínguez-Rodríguez A; Abreu-González P
    Int J Cardiol; 2008 Jul; 127(2):284-7. PubMed ID: 17643519
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction.
    Fuhrmann JT; Schmeisser A; Schulze MR; Wunderlich C; Schoen SP; Rauwolf T; Weinbrenner C; Strasser RH
    Crit Care Med; 2008 Aug; 36(8):2257-66. PubMed ID: 18664782
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Decongestive effects of levosimendan in cardiogenic shock induced by postpartum cardiomyopathy.
    Labbene I; Arrigo M; Tavares M; Hajjej Z; Brandão JL; Tolppanen H; Feliot E; Gayat E; Ferjani M; Mebazaa A
    Anaesth Crit Care Pain Med; 2017 Feb; 36(1):39-42. PubMed ID: 27436451
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Levosimendan does not provide mortality benefit over dobutamine in adult patients with septic shock: A meta-analysis of randomized controlled trials.
    Bhattacharjee S; Soni KD; Maitra S; Baidya DK
    J Clin Anesth; 2017 Jun; 39():67-72. PubMed ID: 28494911
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Levosimendan for treatment of heart failure].
    Yasumura Y
    Nihon Rinsho; 2007 May; 65 Suppl 5():169-72. PubMed ID: 17571380
    [No Abstract]   [Full Text] [Related]  

  • 49. Effect of levosimendan on E/E' ratio in patients with ischemic heart failure.
    Duygu H; Ozerkan F; Nalbantgil S; Zoghi M; Akilli A; Akin M; Nazli C; Ergene O
    Int J Cardiol; 2008 Jan; 123(2):201-3. PubMed ID: 17316845
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A promising new inotrope: levosimendan.
    Fotbolcu H; Duman D
    Anadolu Kardiyol Derg; 2010 Apr; 10(2):176-82. PubMed ID: 20382619
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Levosimendan: current status and future prospects.
    Archan S; Toller W
    Curr Opin Anaesthesiol; 2008 Feb; 21(1):78-84. PubMed ID: 18195615
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Levosimendan: right for the right ventricle?
    Lambermont B; Ghuysen A; Harstein G; D'Orio V
    Crit Care Med; 2007 Aug; 35(8):1995-6. PubMed ID: 17667254
    [No Abstract]   [Full Text] [Related]  

  • 53. Safety of levosimendan and other calcium sensitizers.
    Lehtonen L; Mills-Owens P; Akkila J
    J Cardiovasc Pharmacol; 1995; 26 Suppl 1():S70-6. PubMed ID: 8907134
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The utility of levosimendan in the treatment of heart failure.
    Lehtonen L; Põder P
    Ann Med; 2007; 39(1):2-17. PubMed ID: 17364447
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The clinical experience with levosimendan in anesthesiology and in the intensive care unit.
    Cavana M; Pignataro C; Fraticelli A; Mebazaa A
    Ital Heart J; 2003 May; 4 Suppl 2():61S-64S. PubMed ID: 14635372
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Levosimendan neither improves nor worsens mortality in patients with cardiogenic shock due to ST-elevation myocardial infarction.
    Omerovic E; Råmunddal T; Albertsson P; Holmberg M; Hallgren P; Boren J; Grip L; Matejka G
    Vasc Health Risk Manag; 2010 Sep; 6():657-63. PubMed ID: 20859537
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Levosimendan: first in a new class of inodilator for acute and chronic severe heart failure.
    Cleland JG; Nikitin N; McGowan J
    Expert Rev Cardiovasc Ther; 2004 Jan; 2(1):9-19. PubMed ID: 15038409
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Levosimendan in acute decompensated heart failure: systematic review and meta-analysis.
    Ribeiro RA; Rohde LE; Polanczyk CA
    Arq Bras Cardiol; 2010 Aug; 95(2):230-7. PubMed ID: 20549133
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery: An Update Meta-Analysis and Trial Sequential Analysis.
    Wang B; He X; Gong Y; Cheng B
    Biomed Res Int; 2018; 2018():7563083. PubMed ID: 29854789
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Levosimendan. Clinical indications of a new vasoactive substance].
    Braun JP; Döpfmer U; Kastrup M; Roots I; Borges A; Schneider M; Dohmen P; Kox W; Spies C
    Anaesthesist; 2004 Feb; 53(2):163-7. PubMed ID: 14991194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.